Construction and Validation of Prediction Model of Severe Abdominal Pain Post-Transarterial Chemoembolization in Patients with HBV-Associated Primary Liver Cancer

Objective This study is aimed at constructing and evaluating a prediction model of severe abdominal pain post-transcatheter arterial chemoembolization in patients with HBV-related primary liver cancer. Methods Patients with HBV-associated primary liver cancer who received transarterial chemoembolization (TACE) from March 2019 to March 2022 in the Interventional Therapy Department of our hospital were selected as the subjects, and the included 160 patients were randomly divided into modeling group (n = 120) and validation group (n = 40) in a ratio of 3 : 1. Visual analog scale (VAS) was used to assess pain severity. 120 patients in the modeling group were divided into no/mild abdominal pain group and severe abdominal pain group. The clinical data of the patients, including gender, age, TACE treatment history, vascular invasion, maximum diameter of tumor, infarction degree, preoperative Eastern Oncology Collaboration Group (ECOG) score, and Lipiodol dosage, were analyzed. Receiver operating characteristic (ROC) curve was used to evaluate the predictive value of the prediction model for severe abdominal pain post-TACE. Results A total of 116 patients (72.50%) had severe abdominal pain after TACE. Univariate analysis showed that severe abdominal pain after TACE in the modeling group was associated with TACE treatment history, maximum tumor diameter, infarction degree, and preoperative ECOG score (all P < 0.05), but not related to gender, age, vascular invasion, and Lipiodol dosage (all P > 0.05). Logistic regression analysis showed that TACE treatment history, maximum tumor diameter, infarction degree, and preoperative ECOG score were all independent influencing factors for acute abdominal pain post-TACE in HBV-HCC patients (all P < 0.05). The prediction model equation was Y = −3.673 + 1.722 × TACE treatment history + 1.175 × tumor maximum diameter + 2.064 × infarction degree + 1.555 × preoperative ECOG score. Goodness-of-fit test results showed no significant difference between the established prediction model and the observed value (χ2 = 1.645, P = 0.560) and R2 = 0.821, suggesting that the prediction ability of the model was relatively accurate. ROC analysis results showed that the area under the curve (AUC) of severe abdominal pain after TACE was 0.916 (0.862~0.970) and 0.902 (95% CI: 0.841~0.963) in the modeling group and the verification group, respectively. Conclusion TACE treatment history, tumor maximum diameter, infarction degree, and preoperative ECOG score are independent influencing factors for severe abdominal pain post-TACE in patients with HBV-HCC, and the prediction model established on this basis has good application value.

[1]  H. Ghanaati,et al.  A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma , 2021, Journal of family medicine and primary care.

[2]  Dejun Sun,et al.  Contrasting Trends of Primary Liver Cancer Mortality in Chinese Mongol and Non-Mongol , 2021, Asian Pacific journal of cancer prevention : APJCP.

[3]  Wei Sun,et al.  Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study , 2021, Cancer.

[4]  M. Aschner,et al.  Hypoxia‐Inducible Exosomes Facilitate Liver‐Tropic Premetastatic Niche in Colorectal Cancer , 2021, Hepatology.

[5]  Z. Fu,et al.  Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study , 2021, Hepatology International.

[6]  Lixin Wei,et al.  A TNFR2–hnRNPK Axis Promotes Primary Liver Cancer Development via Activation of YAP Signaling in Hepatic Progenitor Cells , 2021, Cancer Research.

[7]  Jiayin Yang,et al.  Outcome of TACE treatment in HIV infected patients with hepatocellular carcinoma , 2021, Scientific reports.

[8]  S. Murayama,et al.  Transarterial Chemoembolization for the Palliation of Painful Bone Metastases Refractory to First-Line Radiotherapy. , 2020, Journal of vascular and interventional radiology : JVIR.

[9]  I. Kamel,et al.  Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC. , 2020, European journal of radiology.

[10]  M. Ronot,et al.  Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma , 2020, European Radiology.

[11]  K. Lwin.,et al.  The Effects of Supplement Therapy on HCV-Related HCC: a Case Report of a Patient Who Had Undergone TACE for Six Times , 2020, Journal of Gastrointestinal Cancer.

[12]  E. Philip,et al.  Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status , 2020, Cancer.

[13]  S. Zhang,et al.  Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer , 2020, World journal of gastroenterology.

[14]  Michael L. Wang,et al.  Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials , 2020, JAMA network open.

[15]  M. Pompili,et al.  Balloon-Occluded MWA (b-MWA) Followed by Balloon-Occluded TACE (b-TACE): Technical Note on a New Combined Single-Step Therapy for Single Large HCC , 2020, CardioVascular and Interventional Radiology.

[16]  F. Liu,et al.  Repeated postoperative adjuvant TACE after curative hepatectomy improves outcomes of patients with HCC , 2019, Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy.

[17]  Lianyu Chen,et al.  Multimodality palliative treatment with transarterial chemoembolization and high-intensity focused ultrasound for gastric leiomyosarcoma multiple liver metastasis pain , 2019, Medicine.

[18]  D. Mahalingam,et al.  Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC) , 2019, Cancers.

[19]  Guodong Zhang,et al.  Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history , 2019, Medicine.

[20]  S. Miyayama Ultraselective conventional transarterial chemoembolization: When and how? , 2019, Clinical and molecular hepatology.

[21]  P. Tugwell,et al.  Measurement Properties of Visual Analogue Scale, Numeric Rating Scale, and Pain Severity Subscale of the Brief Pain Inventory in Patients With Low Back Pain: A Systematic Review. , 2019, The journal of pain : official journal of the American Pain Society.

[22]  J. Titano,et al.  Transarterial Chemoembolization and Radioembolization across Barcelona Clinic Liver Cancer Stages , 2017, Seminars in Interventional Radiology.